Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 05/10/2026.
- ❌ Price trend failed
- ✅ Growth passed
- ✅ Debt passed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 10.06%
Price change 2019 → 2020: 92.00%
Price change 2020 → 2021: -22.02%
Price change 2021 → 2022: -10.88%
Price change 2022 → 2023: -47.75%
Price change 2023 → 2024: -9.84%
Price change 2024 → 2025: -32.73%
Price change 2025 → 2026: -28.04%
Price change 2026 (year to date): -29.93%
Financial growth
Revenue CAGR (8 years): 16.38%
Earnings CAGR (8 years): 51.19%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.50
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 18.08
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 25.52% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| BIO-UV Group S.A. | 14.9 | 0.50 | +15.8 % | 🔒 |
| Arcure S.A. | – | 1.34 | +18.1 % | – |
| Tractial | 11.6 | 2.05 | −7.8 % | – |
| Touax | – | 5.35 | −3.3 % | – |
| UV Germi S.A. | 78.0 | 0.02 | +6.7 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|